Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jun;12(3):250-3.
doi: 10.1111/iwj.12085. Epub 2013 May 15.

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease

Stefano de Franciscis  1   2 , Luca Gallelli  3 , Luigi Battaglia  4 , Vincenzo Molinari  1 , Rossella Montemurro  1 , Domenico M Stillitano  1 , Gianluca Buffone  1 , Raffaele Serra  1   2
Affiliations
Randomized Controlled Trial

Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease

Stefano de Franciscis et al. Int Wound J. 2015 Jun.

Abstract

Diabetic patients are at high risk of foot ulcerations that may lead to limb amputations with important socio-economic impact. Peripheral vascular disease may be frequently associated in diabetes mellitus type II with its main symptom, intermittent claudication. Many studies reported the known efficacy of cilostazol in treating vascular claudication. Metalloproteinase-9 (MMP-9) seems to be a biochemical marker implicated in chronic wounds and in particular in diabetic foot ulcers. Cilostazol appears to have a lowering effect on MMP-9 levels and this may suggest a beneficial effect in order to prevent or retard the onset of foot ulcer in diabetic patients. In our study, two groups of diabetic patients with peripheral vascular disease were divided into two groups according to the presence of claudication in order to receive cilostazol. Group A (31 patients without claudication) were not eligible to receive cilostazol whereas Group B (47 patients with claudication) received cilostazol administration for 24 weeks (100 mg orally twice daily). Median follow up was of 16 months. During the follow up, 4·25% of patients of Group B and 35·48% of patients of Group A (P < 0·01) showed onset of foot ulceration. Although further randomised and controlled studies are required cilostazol seems to show beneficial effects for primary prevention of diabetic foot ulcers.

Keywords: Cilostazol; Diabetic foot; Intermittent claudication; Metalloproteinase-9; Peripheral vascular disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MMP‐9 plasma levels in cilostazole treated (Group B) and untreated (Group A) patients, measured through ELISA test. The MMP‐9 levels was measured at the time of admission (T = 0) and 3 (T1) and 6 months later (T2). *P < 0·01.
See this image and copyright information in PMC

References

    1. Mackaay AJ, Beks PJ, Dur AH, Bischoff M, Scholma J, Heine RJ, Rauwerda JA. The distribution of peripheral vascular disease in a Dutch Caucasian population: comparison of type II diabetic and non‐diabetic subjects. Eur J Vasc Endovasc Surg 1995;9:170–5. - PubMed
    1. Zubair M, Malik A, Ahmad J. Incidence, risk factors for amputation among patients with diabetic foot ulcer in a North Indian tertiary care hospital. Foot (Edinb) 2012;22:24–30. - PubMed
    1. Heikkinen M, Salmenperä M, Lepäntalo A, Lepäntalo M. Diabetes care for patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2007;33:583–91. - PubMed
    1. Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJV. Diabetic foot ulcers and amputations: estimates of health utility for use in cost‐effectiveness analyses of new treatments. Diabetes Metab 2004;30:549–56. - PubMed
    1. Serra R, Buffone G, Dominijanni A, Molinari V, Montemurro R, de Franciscis S. Applicationif platelet‐rich gel to enhance healing of transmetatarsal amputaions in diabetic dysvascular patients. Int Wound J 2013. DOI: 10.1111/iwj.12052. - DOI - PMC - PubMed

Publication types